Home › Publications

Publications

Full list of peer reviewed articles:

PUBMED link

Selected list of peer reviewed articles:

  • Kawanishi K, Coker JK, Grunddal KV, Dhar C, Hsiao J, Zengler K, Varki N, Varki A, Gordts PLSM. Dietary Neu5Ac Intervention Protects Against Atherosclerosis Associated With Human-Like Neu5Gc Loss. ATVB. 2021 Nov;41(11):2730-2739.
  • Clausen TM, Sandoval DR, Spliid CB, Pihl J, Perrett HR, Painter CD, Narayanan A, Majowicz SA, Kwong EM, McVicar RN, Thacker BE, Glass CA, Yang Z, Torres JL, Golden GJ, Bartels PL, Porell RN, Garretson AF, Laubach L, Feldman J, Yin X, Pu Y, Hauser BM, Caradonna TM, Kellman BP, Martino C, Gordts PLSM, Chanda SK, Schmidt AG, Godula K, Leibel SL, Jose J, Corbett KD, Ward AB, Carlin AF, Esko JD. SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2. Cell. 2020 Nov 12;183(4):1043-1057.e15.
  • Dong J, He M, Li J, Pessentheiner A, Wang C, Zhang J, Sun Y, Wang WT, Zhang Y, Liu J, Wang SC, Huang PH, Gordts PLSM*, Yuan ZY*, Tsimikas S*, Shyy JY*. microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. JCI Insight. 2020 Dec 3;5(23):e143812.
  • Kegulian N, Ramms B, Horton S, Wang B, Trenchevska O, Nedelkov D, Graham MJ, Lee R, Esko JD, Yassine HN, Gordts PL. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors. ATVB, 2019 Oct;39(10):2145-2156.
  • Kawanishi K, Do R, Diaz S, Varki N, Gordts PL*, Varki A*. Human species-specific loss of the CMP-N-acetylneuraminic Acid Hydroxylase fuels atherosclerosis development via intrinsic and extrinsic mechanisms. PNAS, 2019 Aug 6;116(32):16036-16045.
  • Poli M, Anower-E-Khuda F, Asperti M, Ruzzenenti P, Gryzik M, Gordts PL, Arosio P and Esko JD. Hepatic Heparan Sulfate Regulates Hepcidin Expression in Human Hepatocytes and Mice. J Biol Chem. 2019 Sep 6;294(36):13292-13303
  • Tsimikas S*, Gordts PLSM*, Nora C, Yeang C, Witztum JL. Statin therapy increases lipoprotein(a) levels. Eur Heart J. 2019 May 20.
  • Ramms B, Patel S, Nora C, Pessentheiner AR, Chang MW, Green CR, Golden GJ, Secrest P, Krauss RM, Metallo CM, Benner C, Alexander VJ, Witztum JL, Tsimikas S, Esko JD, Gordts PL. ApoC-III ASO Promotes Tissue LPL Activity in Absence of ApoE-Mediated TRL Clearance. J Lipid Res. 2019 Aug;60(8):1379-1395.
  • Tirronen A, Vuorio T, Kettunen S, Hokkanen K, Ramms B, Niskanen H, Laakso H, Kaikkonen MU, Jauhiainen M, Gordts PLSM, Ylä-Herttuala S. Deletion of Lymphangiogenic and Angiogenic Growth Factor VEGF-D Leads to Severe Hyperlipidemia and Delayed Clearance of Chylomicron Remnants. Arterioscler Thromb Vasc Biol. 2018 Oct;38(10):2327-2337.
  • Gordts PLSM, Esko JD. The heparan sulfate proteoglycan grip on hyperlipidemia and atherosclerosis. Matrix Biol. 2018 Oct;71-72:262-282
  • Ramms B, Gordts PLSM. Apolipoprotein C-III in triglyceride-rich lipoprotein metabolism. Curr Opin Lipidol. 2018 Jun;29(3):171-179.
  • Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S. Lipoprotein(a) Mass Levels Increase Significantly According to APOE Genotype – An Analysis of 431 239 Patients. Arterioscler Thromb Vasc Biol. 2017, https://doi.org/10.1161/ATVBAHA.116.308704
  • Gordts PL, Nock R, Son NH, Ramms B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest 2016, Aug:125(8).
  • Akizu N, Cantagrel V, Zaki MS, Wang X, Rosti RO, Dikoglu E, Gelot AB, Rosti B, Vaux KK, Scott EM, Silhavy JL, Schroth J, Copeland B, Schaffer AE, Gordts PL, Esko JD, Buschman M, Napolitano G, Azam M, Al-Gazali L, Selim L, Gamal I, Hadi SA, Mojahedi F, Kayserili H, Masri A, Bastaki L, Temtamy S, Mueller U, Desguerre I, Casanova JL, Gunel M, Gabriel SB, de Lonlay P, Gleeson JG. Biallelic mutations in SNX14 lead to a syndromic form of cerebellar atrophy and lysosome-autophagosome dysfunction. Nature Genetics. 2015 May;47(5):528-3
  • Jimmy Berbee JF, Boon MR, Khedoe PP, Bartelt A,S, Worthmann A, Schlein C, Weigelt C, Kooijman S, Vazirpanah N, Brouwers LPJ, Gordts PL, Esko JD, Hiemstra PS, Havekes LM, Scheja L, Heeren J, Rensen PC.A Central Role for Brown and Beige Adipocytes in Dyslipidemia and Atherosclerosis. Nat Comm. 2015 Mar 10;6:6356.
  • Gordts PL, Foley EM, Lawrence R, Sinha R, Lameda-Diaz C, Deng L, Nock R, Glass CK, Erbilgin A, Lusis AJ, Witztum JL and Esko JD. Reducing Macrophage proteoglycan sulfation increases atherosclerosis and obesity through enhanced Type I interferon signaling. Cell Metab. 2014Nov 4;20(5):813–826.
  • Foley EM*, Gordts PL*, Stanford KI*, Gonzales JC, Lawrence R, Stoddard N, Esko JD. Hepatic Remnant Lipoprotein Clearance by Heparan Sulfate Proteoglycans and Low-Density Lipoprotein Receptors Depend on Dietary Conditions in Mice. Arterioscler Thromb Vasc Biol. 2013 Sep;33(9):2065-74.
  • Bartelt A, Bruns OT, Reimer R, Hohenberg H, Ittrich H, Peldschus K, Kaul MG, Tromsdorf UI, Weller H, Waurisch C, Eychmüller A, Gordts PL, Rinninger F, Bruegelmann K, Freund B, Nielsen P, Merkel M, Heeren J. Brown adipose tissue activity controls triglyceride clearance. Nat Med. 2011 Feb;17(2):200-5
  • Gordts PL, Reekmans S, Lauwers A, Van Dongen A, Verbeek L, Roebroek AJ. Inactivation of the LRP1 intracellular NPxYxxL motif in LDLR-deficient mice enhances postprandial dyslipidemia and atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1258-1264.

Invited Commentaries and Interviews:

  • Pessentheiner AR, Ramms B, Gordts PLSM. ANGPTL3 targeting: The power of versatile lipid-lowering. Atherosclerosis. 2018 Jan;268:185-187.
  • Ramms B and Gordts PL. Dietary nitrate struggles in atherosclerosis. Atherosclerosis. 2016 Feb;245:71-3.
  • Gordts PL, Esko JD. Heparan sulfate proteoglycans fine-tune macrophage inflammation via IFN-β. Cytokine. 2015 Mar;72(1):118-9.
  • Taylor, Jennifer; Gordts, Philip L. S. M. “We Decided to Join Forces to Examine How Macrophage Heparan Sulfate Proteoglycans Impact Atherosclerosis” Source: CIRCULATION, Volume: 125, Issue: 23, Pages: F136-F137, Published: JUN 12 2012